Current and future therapeutic approaches for the treatment of small cell lung cancer

被引：36
|
作者：
Rossi, Antonio [1 ]
Tay, Rebecca [2 ]
Chiramel, Jaseela [2 ]
Prelaj, Arsela [2 ,3 ]
Califano, Raffaele [2 ,4 ,5 ]
机构：
[1] Sci Inst Res & Hlth Care IRCCS Casa Sollievo dell, Div Med Oncol, San Giovanni Rotondo, Italy
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[3] Sapienza Univ Rome, Dept Radiol Pathol & Oncol Sci, Rome, Italy
[4] Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[5] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2018年 / 18卷 / 05期
关键词：
Durvalumab; immunotherapy; ipilimumab; nivolumab; pembrolizumab; rovalpituzumab tesirine; SCLC; second-line; targeted therapy; tremelimumab; PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; ANTIBODY-DRUG CONJUGATE; DOUBLE-BLIND; OPEN-LABEL; 2ND-LINE TREATMENT; THORACIC RADIOTHERAPY; 1ST-LINE TREATMENT;
D O I：
10.1080/14737140.2018.1453361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC.Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC.Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.
引用
收藏
页码：473 / 486
页数：14
相关论文
共 50 条
  • [31] CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer
    Yin, Limei
    Sun, Ping
    Guo, Shujin
    Shuai, Ping
    Zhang, Junlin
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (06):
  • [32] Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
    Di Maio, Massimo
    Costanzo, Raffaele
    Giordano, Pasqualina
    Piccirillo, Maria Carmela
    Sandomenico, Claudia
    Montanino, Agnese
    Carillio, Guido
    Muto, Paolo
    Jones, David R.
    Daniele, Gennaro
    Perrone, Francesco
    Rocco, Gaetano
    Morabito, Alessandro
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (06) : 844 - 851
  • [33] Therapeutic procedure in small cell lung cancer
    Kallianos, Anastasios
    Rapti, Aggeliki
    Zarogoulidis, Paul
    Tsakiridis, Kosmas
    Mpakas, Andreas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Li, Qiang
    Huang, Haidong
    Zaric, Bojan
    Perin, Branislav
    Courcoutsakis, Nikolaos
    Zarogoulidis, Konstantinos
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S420 - S424
  • [34] Immunotherapy for extensive stage small cell lung cancer
    Pacheco, Jose M.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6212 - 6224
  • [35] Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives
    De Mello, Ramon Andrade Bezerra
    Voscaboinik, Rafael
    Luciano, Joao Vittor Pires
    Cremonese, Rafaela Vilela
    Amaral, Giovanna Araujo
    Castelo-Branco, Pedro
    Antoniou, Georgios
    CANCERS, 2022, 14 (01)
  • [36] Squamous cell lung cancer: Current landscape and future therapeutic options
    Lau, Sally C. M.
    Pan, Yuanwang
    Velcheti, Vamsidhar
    Wong, Kwok Kin
    CANCER CELL, 2022, 40 (11) : 1279 - 1293
  • [37] Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
    Rihawi, Karim
    Gelsomino, Francesco
    Sperandi, Francesca
    Melotti, Barbara
    Fiorentino, Michelangelo
    Casolari, Laura
    Ardizzoni, Andrea
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (09) : 353 - 373
  • [38] Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer
    Stinchcombe, Thomas E.
    ONCOLOGIST, 2017, 22 (12) : 1510 - 1517
  • [39] Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches
    Remon, J.
    Pardo, N.
    Martinez-Marti, A.
    Cedres, S.
    Navarro, A.
    Martinez de Castro, A. M.
    Felip, E.
    LUNG CANCER, 2017, 106 : 70 - 75
  • [40] Recent advances in small cell lung cancer: the future is now?
    Luciani, Andrea
    Blasi, Miriam
    Provenzano, Leonardo
    Zonato, Sabrina
    Ferrari, Daris
    MINERVA ENDOCRINOLOGY, 2022, 47 (04): : 460 - 474
12345